Hematologic Disease



Many patients have hematologic issues before and/or after undergoing surgery. Hematologic disorders (such as anemia, bleeding diathesis, or hypercoagulability) can affect perioperative management and outcomes. Therefore, recognizing and correcting these hematologic conditions can significantly reduce perioperative complications. This chapter will focus on the evaluation and management of hematologic issues commonly encountered in surgical patients.


Bleeding Time Polycythemia Vera Idiopathic Thrombocytopenic Purpura Essential Thrombocythemia Platelet Dysfunction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1.  1.
    Shander A, Knight K, Thurer R, Adamson J, Spence R. Prevalence and outcomes of anemia in surgery: a systematic review of the literature. Am J Med. 2004;116(Suppl 7A):58S-69S.PubMedCrossRefGoogle Scholar
  2.  2.
    Carson JL, Duff A, Poses RM, et al. Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet. 1996;348(9034):1055-1060.PubMedCrossRefGoogle Scholar
  3.  3.
    Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion requirements in critical care investigators, Canadian Critical Care Trials Group. N Engl J Med. 1999;340(6):409-417.PubMedCrossRefGoogle Scholar
  4.  4.
    Vincent JL, Baron JF, Reinhart K, et al. Anemia and blood transfusion in critically ill patients. JAMA. 2002;288(12):1499-1507.PubMedCrossRefGoogle Scholar
  5.  5.
    Corwin HL, Gettinger A, Pearl RG, et al. The CRIT study: anemia and blood transfusion in the critically ill–current clinical practice in the United States. Crit Care Med. 2004;32(1):­39-52.PubMedCrossRefGoogle Scholar
  6.  6.
    Vincent JL, Sakr Y, Sprung C, Harboe S, Damas P. Are blood transfusions associated with greater mortality rates? Results of the sepsis occurrence in acutely Ill patients study. Anesthesiology. 2008;108(1):31-39.PubMedCrossRefGoogle Scholar
  7.  7.
    Testa U. Erythropoietic stimulating agents. Expert Opin Emerg Drugs. 2010;15(1):119-138.PubMedCrossRefGoogle Scholar
  8.  8.
    Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. N Engl J Med. 1995;333(4):206-214.PubMedCrossRefGoogle Scholar
  9.  9.
    McMullin MF. The classification and diagnosis of erythrocytosis. Int J Lab Hematol. 2008;30(6):447-459.PubMedGoogle Scholar
  10. 10.
    Ruggeri M, Rodeghiero F, Tosetto A, et al. Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood. 2008;111(2): 666-671.PubMedCrossRefGoogle Scholar
  11. 11.
    Wasserman LR, Gilbert HS. Surgery in polycythemia vera. N Engl J Med. 1963;269(23): 1226-1230.PubMedCrossRefGoogle Scholar
  12. 12.
    Solberg LA Jr. Therapeutic options for essential thrombocythemia and polycythemia vera. Semin Oncol. 2002;29(3 Suppl 10):10-15.PubMedCrossRefGoogle Scholar
  13. 13.
    Schaefer H, Engert A, Grass G, et al. Perioperative granulocyte colony-stimulating factor does not prevent severe infections in patients undergoing esophagectomy for esophageal cancer: a randomized placebo-controlled clinical trial. Ann Surg. 2004;240(1):68-75.PubMedCrossRefGoogle Scholar
  14. 14.
    Schneider C, von Aulock S, Zedler S, Schinkel C, Hartung T, Faist E. Perioperative recombinant human granulocyte colony-stimulating factor (Filgrastim) treatment prevents immunoinflammatory dysfunction associated with major surgery. Ann Surg. 2004;239(1):75-81.PubMedCrossRefGoogle Scholar
  15. 15.
    Massey E, Paulus U, Doree C, Stanworth S. Granulocyte transfusions for preventing infections in patients with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev. 2009;(1):CD005341.Google Scholar
  16. 16.
    Liumbruno G, Bennardello F, Lattanzio A, Piccoli P, Rossetti G. Recommendations for the transfusion of plasma and platelets. Blood Transfus. 2009;7(2):132-150.PubMedGoogle Scholar
  17. 17.
    Finazzi G, Barbui T. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia. 2008;22(8):1494-1502.PubMedCrossRefGoogle Scholar
  18. 18.
    Emadi A, Spivak JL. Anagrelide: 20 years later. Expert Rev Anticancer Ther. 2009;9(1): 37-50.PubMedCrossRefGoogle Scholar
  19. 19.
    Michiels JJ, van Vliet HH, Berneman Z, Schroyens W, Gadisseur A. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings. Acta Haematol. 2009;121(2–3):167-176.PubMedCrossRefGoogle Scholar
  20. 20.
    Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) expert panel report (USA). Haemophilia. 2008;14(2):171-232.PubMedCrossRefGoogle Scholar
  21. 21.
    Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Dent Assoc. 2007;138(5):652-655.PubMedGoogle Scholar
  22. 22.
    Gomez K, Bolton-Maggs P. Factor XI deficiency. Haemophilia. 2008;14:1183-1189.PubMedGoogle Scholar
  23. 23.
    The American Society of Hematology ITP Practice Guideline Panel. Diagnosis and treatment of idiopathic thrombocytopenic purpura: recommendations of the American Society of Hematology. The American Society of Hematology ITP Practice Guideline Panel. Ann Intern Med. 1997;126(4):319-326.Google Scholar
  24. 24.
    Kitchens CS. Thrombocytopenia and thrombosis in disseminated intravascular coagulation (DIC). Hematology Am Soc Hematol Educ Program. 2009;240–246.Google Scholar
  25. 25.
    Sihler KC, Napolitano LM. Massive transfusion: new insights. Chest. 2009;136(6): 1654-1667.PubMedCrossRefGoogle Scholar
  26. 26.
    Coppola A, Tufano A, Cerbone AM, Di Minno G. Inherited thrombophilia: implications for prevention and treatment of venous thromboembolism. Semin Thromb Hemost. 2009;35(7): 683-694.PubMedCrossRefGoogle Scholar
  27. 27.
    Chee YL, Crawford JC, Watson HG, Greaves M. Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures. Br J Haematol. 2008;140(5):496-504.PubMedCrossRefGoogle Scholar
  28. 28.
    Pfeifer K, Abu-Hajir M. Coagulation disorders. In: Cohn SL, Smetana GW, Weed HG, eds. Perioperative Medicine-Just the Facts. New York: McGraw Hill; 2006.Google Scholar

Copyright information

© Springer-Verlag London Limited 2011

Authors and Affiliations

  1. 1.Department of General Internal MedicineThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations